Concepedia

Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases

Millie D. Long, Kimberly N. Weaver, Xian Zhang, Kelly Chun, Michael D. Kappelman, Runa Watkins, Marla C. Dubinsky, Arthur Kastl, Athos Bousvaros, Jennifer Strople,

Clinical Gastroenterology and Hepatology · 2022 · 36 citations · 8 references

DOIFull text

Open access

Concepts

References

8

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021

Wesley H. Self, Mark W. Tenforde, Jillian P. Rhoads et al. · MMWR Morbidity and Mortality Weekly Report · 2021 · 455 citations · Full text

, , +16

SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting

Corey A. Siegel, Gil Melmed, Dermot McGovern et al. · Gut · 2021 · 185 citations · Full text

, , +17

Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease

Michael D. Kappelman, Kimberly N. Weaver, Margie Boccieri et al. · Gastroenterology · 2021 · 86 citations · Full text

, , +17

Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses

V. Gounant, Valentine Marie Ferré, Ghassen Soussi et al. · Journal of Thoracic Oncology · 2021 · 62 citations · Full text

, , +12

Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment

Tania Buttiron Webber, Nicoletta Provinciali, Marco Musso et al. · European Journal of Cancer · 2021 · 46 citations · Full text

, , +17